Global Killed-type Poultry Vaccine Market Outlook, InDepth Analysis & Forecast to 2032家禽用死菌ワクチンの世界市場 2026-2032年 The global Killed-type Poultry Vaccine market is projected to grow from US$ 1455 million in 2025 to US$ 1987 million by 2032, at a CAGR of 4.6% (2026-2032), driven by critical product segments and ... もっと見る
図表リストList of TablesTable 1. Global Killed-type Poultry Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Table 2. Global Killed-type Poultry Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million) Table 3. Global Killed-type Poultry Vaccine Market Size Growth Rate by Function, 2021 vs 2025 vs 2032 (US$ Million) Table 4. Global Killed-type Poultry Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Table 5. Global Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 6. Global Killed-type Poultry Vaccine Revenue by Region (US$ Million), 2021-2026 Table 7. Global Killed-type Poultry Vaccine Revenue by Region (US$ Million), 2027-2032 Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 9. Global Killed-type Poultry Vaccine Revenue by Players (US$ Million), 2021-2026 Table 10. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Players (2021-2026) Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue) Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Killed-type Poultry Vaccine Revenue, 2025 Table 13. Global Killed-type Poultry Vaccine Average Gross Margin (%) by Player (2021 vs 2025) Table 14. Global Killed-type Poultry Vaccine Companies Headquarters Table 15. Global Killed-type Poultry Vaccine Market Concentration Ratio (CR5) Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment Table 18. Global Killed-type Poultry Vaccine Revenue by Type (US$ Million), 2021-2026 Table 19. Global Killed-type Poultry Vaccine Revenue by Type (US$ Million), 2027-2032 Table 20. Global Killed-type Poultry Vaccine Revenue by Antigen Combination (US$ Million), 2021-2026 Table 21. Global Killed-type Poultry Vaccine Revenue by Antigen Combination (US$ Million), 2027-2032 Table 22. Global Killed-type Poultry Vaccine Revenue by Function (US$ Million), 2021-2026 Table 23. Global Killed-type Poultry Vaccine Revenue by Function (US$ Million), 2027-2032 Table 24. Key Product Attributes and Differentiation Table 25. Global Killed-type Poultry Vaccine Revenue by Application (US$ Million), 2021-2026 Table 26. Global Killed-type Poultry Vaccine Revenue by Application (US$ Million), 2027-2032 Table 27. Killed-type Poultry Vaccine High-Growth Sectors Demand CAGR (2026-2032) Table 28. Top Customers by Region Table 29. Top Customers by Application Table 30. North America Killed-type Poultry Vaccine Growth Accelerators and Market Barriers Table 31. North America Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 32. Europe Killed-type Poultry Vaccine Growth Accelerators and Market Barriers Table 33. Europe Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million) Table 34. Asia-Pacific Killed-type Poultry Vaccine Growth Accelerators and Market Barriers Table 35. Asia-Pacific Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 36. Central and South America Killed-type Poultry Vaccine Investment Opportunities and Key Challenges Table 37. Central and South America Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 38. Middle East and Africa Killed-type Poultry Vaccine Investment Opportunities and Key Challenges Table 39. Middle East and Africa Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 40. MSD Animal Health(Merck) Corporation Information Table 41. MSD Animal Health(Merck) Description and Major Businesses Table 42. MSD Animal Health(Merck) Product Features and Attributes Table 43. MSD Animal Health(Merck) Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. MSD Animal Health(Merck) Revenue Proportion by Product in 2025 Table 45. MSD Animal Health(Merck) Revenue Proportion by Application in 2025 Table 46. MSD Animal Health(Merck) Revenue Proportion by Geographic Area in 2025 Table 47. MSD Animal Health(Merck) Killed-type Poultry Vaccine SWOT Analysis Table 48. MSD Animal Health(Merck) Recent Developments Table 49. Zoetis Corporation Information Table 50. Zoetis Description and Major Businesses Table 51. Zoetis Product Features and Attributes Table 52. Zoetis Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Zoetis Revenue Proportion by Product in 2025 Table 54. Zoetis Revenue Proportion by Application in 2025 Table 55. Zoetis Revenue Proportion by Geographic Area in 2025 Table 56. Zoetis Killed-type Poultry Vaccine SWOT Analysis Table 57. Zoetis Recent Developments Table 58. Boehringer Ingelheim Corporation Information Table 59. Boehringer Ingelheim Description and Major Businesses Table 60. Boehringer Ingelheim Product Features and Attributes Table 61. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Boehringer Ingelheim Revenue Proportion by Product in 2025 Table 63. Boehringer Ingelheim Revenue Proportion by Application in 2025 Table 64. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025 Table 65. Boehringer Ingelheim Killed-type Poultry Vaccine SWOT Analysis Table 66. Boehringer Ingelheim Recent Developments Table 67. Ceva Santé Animale Corporation Information Table 68. Ceva Santé Animale Description and Major Businesses Table 69. Ceva Santé Animale Product Features and Attributes Table 70. Ceva Santé Animale Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Ceva Santé Animale Revenue Proportion by Product in 2025 Table 72. Ceva Santé Animale Revenue Proportion by Application in 2025 Table 73. Ceva Santé Animale Revenue Proportion by Geographic Area in 2025 Table 74. Ceva Santé Animale Killed-type Poultry Vaccine SWOT Analysis Table 75. Ceva Santé Animale Recent Developments Table 76. Elanco Animal Health Corporation Information Table 77. Elanco Animal Health Description and Major Businesses Table 78. Elanco Animal Health Product Features and Attributes Table 79. Elanco Animal Health Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Elanco Animal Health Revenue Proportion by Product in 2025 Table 81. Elanco Animal Health Revenue Proportion by Application in 2025 Table 82. Elanco Animal Health Revenue Proportion by Geographic Area in 2025 Table 83. Elanco Animal Health Killed-type Poultry Vaccine SWOT Analysis Table 84. Elanco Animal Health Recent Developments Table 85. HIPRA Corporation Information Table 86. HIPRA Description and Major Businesses Table 87. HIPRA Product Features and Attributes Table 88. HIPRA Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. HIPRA Recent Developments Table 90. Vaxxinova Corporation Information Table 91. Vaxxinova Description and Major Businesses Table 92. Vaxxinova Product Features and Attributes Table 93. Vaxxinova Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Vaxxinova Recent Developments Table 95. QYH Biotech Corporation Information Table 96. QYH Biotech Description and Major Businesses Table 97. QYH Biotech Product Features and Attributes Table 98. QYH Biotech Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. QYH Biotech Recent Developments Table 100. Pulike Corporation Information Table 101. Pulike Description and Major Businesses Table 102. Pulike Product Features and Attributes Table 103. Pulike Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Pulike Recent Developments Table 105. Harbin Pharmaceutical Group Corporation Information Table 106. Harbin Pharmaceutical Group Description and Major Businesses Table 107. Harbin Pharmaceutical Group Product Features and Attributes Table 108. Harbin Pharmaceutical Group Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Harbin Pharmaceutical Group Recent Developments Table 110. Nisseiken Corporation Information Table 111. Nisseiken Description and Major Businesses Table 112. Nisseiken Product Features and Attributes Table 113. Nisseiken Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Nisseiken Recent Developments Table 115. Hester Biosciences Corporation Information Table 116. Hester Biosciences Description and Major Businesses Table 117. Hester Biosciences Product Features and Attributes Table 118. Hester Biosciences Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Hester Biosciences Recent Developments Table 120. Globion India Corporation Information Table 121. Globion India Description and Major Businesses Table 122. Globion India Product Features and Attributes Table 123. Globion India Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Globion India Recent Developments Table 125. Venkys India Corporation Information Table 126. Venkys India Description and Major Businesses Table 127. Venkys India Product Features and Attributes Table 128. Venkys India Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Venkys India Recent Developments Table 130. Bioveta Corporation Information Table 131. Bioveta Description and Major Businesses Table 132. Bioveta Product Features and Attributes Table 133. Bioveta Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Bioveta Recent Developments Table 135. Jilin Zhengye Corporation Information Table 136. Jilin Zhengye Description and Major Businesses Table 137. Jilin Zhengye Product Features and Attributes Table 138. Jilin Zhengye Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Jilin Zhengye Recent Developments Table 140. Yebio Corporation Information Table 141. Yebio Description and Major Businesses Table 142. Yebio Product Features and Attributes Table 143. Yebio Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Yebio Recent Developments Table 145. Sinder Corporation Information Table 146. Sinder Description and Major Businesses Table 147. Sinder Product Features and Attributes Table 148. Sinder Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Sinder Recent Developments Table 150. DHN Corporation Information Table 151. DHN Description and Major Businesses Table 152. DHN Product Features and Attributes Table 153. DHN Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. DHN Recent Developments Table 155. JinYu Biotechnology Corporation Information Table 156. JinYu Biotechnology Description and Major Businesses Table 157. JinYu Biotechnology Product Features and Attributes Table 158. JinYu Biotechnology Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. JinYu Biotechnology Recent Developments Table 160. Guangzhou South China Biological Medicine Corporation Information Table 161. Guangzhou South China Biological Medicine Description and Major Businesses Table 162. Guangzhou South China Biological Medicine Product Features and Attributes Table 163. Guangzhou South China Biological Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 164. Guangzhou South China Biological Medicine Recent Developments Table 165. Technologies, Platforms and Infrastructure Table 166. Distributors List Table 167. Market Trends and Market Evolution Table 168. Market Drivers and Opportunities Table 169. Market Challenges, Risks, and Restraints Table 170. Research Programs/Design for This Report Table 171. Key Data Information from Secondary Sources Table 172. Key Data Information from Primary Sources List of Figures Figure 1. Global Killed-type Poultry Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Figure 2. Newcastle Disease Vaccines Product Picture Figure 3. Infectious Bronchitis Vaccines Product Picture Figure 4. Others Product Picture Figure 5. Global Killed-type Poultry Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million) Figure 6. Monovalent Vaccines Product Picture Figure 7. Multivalent / Combination Vaccines Product Picture Figure 8. Global Killed-type Poultry Vaccine Market Size Growth Rate by Function, 2021 vs 2025 vs 2032 (US$ Million) Figure 9. Preventive Vaccines Product Picture Figure 10. Prime Vaccines Product Picture Figure 11. Booster Vaccines Product Picture Figure 12. Global Killed-type Poultry Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Figure 13. Broiler Farming Figure 14. Layer Farming Figure 15. Breeder Farming Figure 16. Others Figure 17. Killed-type Poultry Vaccine Report Years Considered Figure 18. Global Killed-type Poultry Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032 Figure 19. Global Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 20. Global Killed-type Poultry Vaccine Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Figure 21. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Region (2021-2032) Figure 22. Global Killed-type Poultry Vaccine Revenue-Based Market Share Ranking (2025) Figure 23. Tier Distribution by Revenue Contribution (2021 vs 2025) Figure 24. Newcastle Disease Vaccines Revenue-Based Market Share by Player in 2025 Figure 25. Infectious Bronchitis Vaccines Revenue-Based Market Share by Player in 2025 Figure 26. Others Revenue-Based Market Share by Player in 2025 Figure 27. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Type (2021-2032) Figure 28. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Antigen Combination (2021-2032) Figure 29. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Function (2021-2032) Figure 30. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Application (2021-2032) Figure 31. North America Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 32. North America Top 5 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025 Figure 33. North America Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 34. US Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 35. Canada Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 36. Mexico Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 37. Europe Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 38. Europe Top 5 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025 Figure 39. Europe Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 40. Germany Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 41. France Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 42. U.K. Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 43. Italy Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 44. Russia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 45. Asia-Pacific Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 46. Asia-Pacific Top 8 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025 Figure 47. Asia-Pacific Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 48. Indonesia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 49. Japan Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 50. South Korea Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 51. Australia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 52. India Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 53. Indonesia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 54. Vietnam Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 55. Malaysia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 56. Philippines Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 57. Singapore Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 58. Central and South America Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 59. Central and South America Top 5 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025 Figure 60. Central and South America Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 61. Brazil Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 62. Argentina Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 63. Middle East and Africa Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 64. Middle East and Africa Top 5 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025 Figure 65. Middle East and Africa Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 66. GCC Countries Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 67. Israel Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 68. Egypt Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 69. South Africa Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 70. Killed-type Poultry Vaccine Value Chain Mapping Figure 71. Channels of Distribution (Direct Vs Distribution) Figure 72. Bottom-up and Top-down Approaches for This Report Figure 73. Data Triangulation Figure 74. Key Executives Interviewed
SummaryThe global Killed-type Poultry Vaccine market is projected to grow from US$ 1455 million in 2025 to US$ 1987 million by 2032, at a CAGR of 4.6% (2026-2032), driven by critical product segments and diverse end‑use applications.Killed-type Poultry Vaccines are veterinary biological products containing viral, bacterial, or other pathogen-derived antigens that have been propagated and then completely inactivated by methods such as formaldehyde or beta-propiolactone, eliminating replication capability while retaining immunogenicity. They are generally formulated with mineral oil, vegetable oil, or other adjuvants as injectable emulsions and are used for prevention, priming, or booster immunization in chickens and other poultry. By disease type, the product is classified into Newcastle Disease Vaccines, Infectious Bronchitis Vaccines, and Others; by Antigen Combination, into Monovalent Vaccines and Multivalent/Combination Vaccines; and by Function, into Preventive Vaccines, Prime Vaccines, and Booster Vaccines. Mainstream products use water-in-oil or related oil-emulsion systems and are administered intramuscularly or subcutaneously, typically at approximately 0.3–0.5 mL per bird. Potency is commonly evaluated using PD50, HI antibody titers, or VN antibody titers. Unlike live vaccines, these products do not replicate or spread vaccine virus after administration and are particularly suited to establishing durable humoral immunity in layers and breeders before the laying period. Key Findings The average industry gross margin in 2025 is approximately 45%–65%. Newcastle Disease Vaccines represent the largest segment, with mainstream 0.5 mL-per-bird oil-emulsion products providing ≥50 PD50 or inducing ≥4.0 log2 HI at 1/50 dose. Layer Farming represents the largest downstream application. MSD Animal Health, Zoetis, Boehringer Ingelheim, Ceva Santé Animale, and Elanco Animal Health are positioned among the leading global suppliers. Market Trends The product is evolving from conventional monovalent oil emulsions toward multivalent combinations, higher antigen loading, reduced injection reactions, and longer-lasting immunity. Conventional monovalent Newcastle Disease products retain important baseline demand, but layers and breeders are increasingly vaccinated with combination products covering ND, IB, IBD, EDS, avian rhinotracheitis, or Salmonella in a single injection. MSD offers IB+ND, IB+G+ND, and RT+IB Multi+ND+EDS combinations, while Zoetis Maternavac 4 combines IBD, ND, Reovirus, and IB protection. Future technology development will focus on emulsion stability, reduced local tissue reactions, broader antigen combinations, and digital injection systems that improve dose and administration-site consistency. Market Dynamics Drivers Demand for the product is primarily driven by the long production cycles of layers and breeders, the need to prevent declines in egg production, maintenance of flock antibody levels, and transfer of maternal antibodies to progeny. WOAH notes that inactivated Newcastle vaccines are commonly used as boosters following live priming before the onset of lay and can generate high and persistent serum antibody titers. Layer production cycles are substantially longer than broiler cycles, and ND, IB, or EDS infections after the onset of lay can directly affect egg output and quality, creating strong economic value for pre-lay injectable boosters. Breeder flocks additionally require high maternal antibody levels against diseases such as IBD and Reovirus to provide early passive protection to chicks. Restraints The largest restraint is the need for individual injection, which results in higher labor requirements and greater operational complexity than spray- or drinking-water-administered live vaccines. WOAH notes that inactivated vaccines are generally more expensive than live vaccines, require handling and injection of individual birds, and require greater antigen quantities because the antigen cannot replicate in the host. Oil emulsions may also cause local inflammation, nodules, or injection-site reactions, while incorrect administration can affect immunity and carcass quality. Products generally require refrigerated storage at 2–8°C and should not be frozen, as freezing or emulsion breakdown can impair stability. Their use also frequently depends on an appropriate live-vaccine priming program. Opportunities Future opportunities are concentrated in Multivalent/Combination Vaccines, long-duration protection for layers, maternal-antibody management in breeders, and precision injection systems. Combining multiple antigens reduces bird handling and injection frequency and therefore has substantial value for large layer and breeder operations. Boehringer Ingelheim's Gallimune 407 combines ND, IB, EDS, and avian rhinotracheitis antigens in one oil-emulsion product, while Zoetis Poulvac SE-ND-IB combines Salmonella, ND, and IB in one killed water-in-oil emulsion. Future portfolios can also incorporate regional IB variants, avian influenza subtypes, and bacterial pathogens, while automated injection and digital tracking systems can improve vaccination quality across large flocks. Challenges The core challenge is achieving complete inactivation while preserving sufficient antigenicity and maintaining long-term emulsion and batch stability. Inadequate inactivation creates a biosafety risk, while excessive chemical treatment may damage important antigenic epitopes and reduce potency. Newcastle Disease and Infectious Bronchitis viruses also have multiple strains and antigenic variants, and the degree of antigenic matching with field strains can influence protection. Multivalent products introduce additional challenges because different antigens may interact immunologically, requiring careful control of antigen ratios, adjuvant systems, and formulation consistency. As the number of antigens increases, manufacturers must simultaneously manage viscosity, injection convenience, local reactions, and duration of antibody response. Industry Chain Analysis The upstream supply chain mainly includes SPF embryonated eggs, avian or other cell-culture substrates, master and working seed viruses, culture media, inactivating agents, mineral- or vegetable-oil adjuvants, emulsifiers, sterile vials and packaging, as well as bioreactors, filling equipment, and cold-chain infrastructure. Midstream production includes pathogen propagation, antigen harvest, concentration and purification, inactivation, validation of complete inactivation, antigen quantification, oil-water emulsification, aseptic filling, potency testing, safety testing, and stability control. WOAH notes that inactivated Newcastle vaccine antigen may be obtained from allantoic fluid, inactivated with formaldehyde or beta-propiolactone, and incorporated into mineral- or vegetable-oil emulsions. Downstream demand comes from Broiler Farming, Layer Farming, Breeder Farming, and Other poultry operations through veterinary distributors, integrated poultry companies, and veterinary service networks, together with injectors, serological monitoring, and refrigerated logistics. Segment Insights By disease type, Newcastle Disease Vaccines represent the core segment. Nobilis Newcavac is a representative monovalent product based on inactivated Clone 30 antigen, administered at 0.5 mL per bird and containing at least 50 PD50 or inducing ≥4.0 log2 HI at 1/50 dose. Infectious Bronchitis Vaccines commonly use Massachusetts antigens such as M41 and are frequently combined with ND. Other categories include IBD, EDS, Reovirus, avian rhinotracheitis, Salmonella, and avian influenza. By Antigen Combination and Function, Multivalent/Combination Vaccines represent the major high-value direction. Products can integrate three, four, or more antigens in one dose; RT+IB Multi+ND+EDS, for example, uses a 0.5 mL dose containing avian rhinotracheitis, two IB antigens, ND, and EDS antigens. Although the product can be used for preventive and prime immunization, its most characteristic function is as a Booster Vaccine. Nobilis Newcavac is intended for live-primed layers and breeders and is normally administered at least four weeks before the expected onset of lay, supporting a standardized “live prime + multivalent inactivated booster” strategy. Downstream Market Opportunities Layer Farming represents the largest application because the long production cycle and economic importance of egg output require durable humoral protection against ND, IB, EDS, and related diseases before the onset of lay. Breeder Farming is another important high-value application because protection of the parent flock must be combined with high maternal-antibody transfer against diseases such as IBD and Reovirus. Zoetis Maternavac 4 is intended for chickens 16–22 weeks of age and combines IBD, ND, Reovirus, and IB antigens to support breeder and progeny protection. Broiler Farming uses the product more selectively because of shorter production cycles and the cost of individual injection, although demand remains in high-disease-pressure, slow-growing broiler, and selected ND or avian-influenza programs. Artificial intelligence is not part of the vaccine itself, but it can analyze antibody titers, egg-production curves, mortality, and outbreak data to optimize booster timing and use vision systems to monitor injection accuracy and missed birds. Regional Insights Asia-Pacific is an important production and consumption region because of its large layer, breeder, and broiler industries and continued demand for control of ND, IB, avian influenza, and other diseases. Chinese participants include QYH Biotech, Pulike, Harbin Pharmaceutical Group, Jilin Zhengye, Shandong Huahong Biological Engineering, Yebio, Sinder, DHN, JinYu Biotechnology, and Guangzhou South China Biological Medicine, while India includes Hester Biosciences, Globion India, and Venky's India. Europe has established suppliers such as Boehringer Ingelheim, Ceva, HIPRA, Vaxxinova, and Bioveta and strong expertise in multivalent oil-emulsion vaccines; HIPRA offers monovalent ND, ND+IB, and four-way inactivated injectable emulsions. North America places strong emphasis on Salmonella control, breeder vaccination, and multivalent killed products, with Zoetis and Elanco maintaining broad inactivated portfolios. Competitive Landscape Analysis The product market has substantial barriers in seed-strain resources, SPF production, inactivation validation, oil-emulsion technology, cold-chain management, and regulatory approval. Representative leading players include MSD Animal Health (Merck), Zoetis, Boehringer Ingelheim, Ceva Santé Animale, and Elanco Animal Health. MSD's Nobilis portfolio extends from monovalent Newcavac to IB+ND, IB+G+ND, and RT+IB Multi+ND+EDS combinations; Zoetis uses Poulvac SE-ND-IB and Maternavac products to cover Salmonella, ND, IB, IBD, and Reovirus; Boehringer Ingelheim competes through Gallimune and Volvac multivalent oil-emulsion platforms; and Elanco's AviPro portfolio includes combinations targeting ND, IB, IBD, and Reovirus. Competition is shifting from basic antigen potency toward broader antigen combinations, duration of immunity, lower injection reactions, maternal-antibody management, and complete vaccination-program services. Report Scope This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Killed-type Poultry Vaccine market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers. By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern. Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends. Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths. A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand. Market Segmentation By Company MSD Animal Health(Merck) Zoetis Boehringer Ingelheim Ceva Santé Animale Elanco Animal Health HIPRA Vaxxinova QYH Biotech Pulike Harbin Pharmaceutical Group Nisseiken Hester Biosciences Globion India Venkys India Bioveta Jilin Zhengye Yebio Sinder DHN JinYu Biotechnology Guangzhou South China Biological Medicine Segment by Type Newcastle Disease Vaccines Infectious Bronchitis Vaccines Others Segment by Antigen Combination Monovalent Vaccines Multivalent / Combination Vaccines Segment by Function Preventive Vaccines Prime Vaccines Booster Vaccines Segment by Application Broiler Farming Layer Farming Breeder Farming Others Segment by Region North America United States Canada Mexico Asia-Pacific China Japan South Korea India Australia Vietnam Indonesia Malaysia Philippines Singapore Rest of Asia Europe Germany U.K. France Italy Spain Benelux Russia Rest of Europe Central and South America Brazil Argentina Rest of Central and South America Middle East & Africa GCC Countries Egypt Israel South Africa Rest of MEA Chapter Outline Chapter 1: Defines the Killed-type Poultry Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies Chapter 14: Actionable conclusions and strategic recommendations. Why This Report Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to: Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5). Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence. Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11). Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14). Leverage this 360° intelligence to turn market complexity into actionable competitive advantage. Table of Contents1 Study Coverage1.1 Introduction to Killed-type Poultry Vaccine: Definition, Properties, and Key Attributes 1.2 Market Segmentation by Type 1.2.1 Global Killed-type Poultry Vaccine Market Size by Type, 2021 vs 2025 vs 2032 1.2.2 Newcastle Disease Vaccines 1.2.3 Infectious Bronchitis Vaccines 1.2.4 Others 1.3 Market Segmentation by Antigen Combination 1.3.1 Global Killed-type Poultry Vaccine Market Size by Antigen Combination, 2021 vs 2025 vs 2032 1.3.2 Monovalent Vaccines 1.3.3 Multivalent / Combination Vaccines 1.4 Market Segmentation by Function 1.4.1 Global Killed-type Poultry Vaccine Market Size by Function, 2021 vs 2025 vs 2032 1.4.2 Preventive Vaccines 1.4.3 Prime Vaccines 1.4.4 Booster Vaccines 1.5 Market Segmentation by Application 1.5.1 Global Killed-type Poultry Vaccine Market Size by Application, 2021 vs 2025 vs 2032 1.5.2 Broiler Farming 1.5.3 Layer Farming 1.5.4 Breeder Farming 1.5.5 Others 1.6 Assumptions and Limitations 1.7 Study Objectives 1.8 Years Considered 2 Executive Summary 2.1 Global Killed-type Poultry Vaccine Revenue Estimates and Forecasts (2021-2032) 2.2 Global Killed-type Poultry Vaccine Revenue by Region 2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032 2.2.2 Historical and Forecasted Revenue by Region (2021-2032) 2.2.3 Global Revenue-Based Market Share by Region (2021-2032) 2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends 3 Competitive Landscape 3.1 Global Killed-type Poultry Vaccine Players’ Revenue Rankings and Profitability 3.1.1 Global Revenue (Value) by Players (2021-2026) 3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025) 3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3) 3.1.4 Gross Margin by Top Players (2021 vs 2025) 3.2 Global Killed-type Poultry Vaccine Companies Headquarters and Service Footprint 3.3 Key Player Market Share by Product Type 3.3.1 Newcastle Disease Vaccines: Market Share by Key Players 3.3.2 Infectious Bronchitis Vaccines: Market Share by Key Players 3.3.3 Others: Market Share by Key Players 3.4 Global Killed-type Poultry Vaccine Market Concentration and Dynamics 3.4.1 Global Market Concentration 3.4.2 Market Entry and Exit Analysis 3.4.3 Strategic Moves: M&A, Expansion, R&D Investment 4 Product Segmentation 4.1 Global Killed-type Poultry Vaccine Market by Type 4.1.1 Global Revenue by Type (2021-2032) 4.1.2 Global Revenue-Based Market Share by Type (2021-2032) 4.2 Global Killed-type Poultry Vaccine Market by Antigen Combination 4.2.1 Global Revenue by Antigen Combination (2021-2032) 4.2.2 Global Revenue-Based Market Share by Antigen Combination (2021-2032) 4.3 Global Killed-type Poultry Vaccine Market by Function 4.3.1 Global Revenue by Function (2021-2032) 4.3.2 Global Revenue-Based Market Share by Function (2021-2032) 4.4 Key Product Attributes and Differentiation 4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk 4.5.1 High-Growth Niches and Adoption Drivers 4.5.2 Profitability Hotspots and Cost Drivers 4.5.3 Substitution Threats 5 Downstream Applications and Customers 5.1 Global Killed-type Poultry Vaccine Revenue by Application 5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032) 5.1.2 Revenue-Based Market Share by Application (2021-2032) 5.1.3 High-Growth Application Identification 5.1.4 Emerging Application Case Studies 5.2 Downstream Customer Analysis 5.2.1 Top Customers by Region 5.2.2 Top Customers by Application 6 North America 6.1 North America Market Size (2021-2032) 6.2 North America Key Players’ Revenue in 2025 6.3 North America Killed-type Poultry Vaccine Market Size by Application (2021-2032) 6.4 North America Growth Accelerators and Market Barriers 6.5 North America Killed-type Poultry Vaccine Market Size by Country 6.5.1 North America Revenue Trends by Country 6.5.2 US 6.5.3 Canada 6.5.4 Mexico 7 Europe 7.1 Europe Market Size (2021-2032) 7.2 Europe Key Players’ Revenue in 2025 7.3 Europe Killed-type Poultry Vaccine Market Size by Application (2021-2032) 7.4 Europe Growth Accelerators and Market Barriers 7.5 Europe Killed-type Poultry Vaccine Market Size by Country 7.5.1 Europe Revenue Trends by Country 7.5.2 Germany 7.5.3 France 7.5.4 U.K. 7.5.5 Italy 7.5.6 Russia 8 Asia-Pacific 8.1 Asia-Pacific Market Size (2021-2032) 8.2 Asia-Pacific Key Players’ Revenue in 2025 8.3 Asia-Pacific Killed-type Poultry Vaccine Market Size by Application (2021-2032) 8.4 Asia-Pacific Growth Accelerators and Market Barriers 8.5 Asia-Pacific Killed-type Poultry Vaccine Market Size by Region 8.5.1 Asia-Pacific Revenue Trends by Region 8.6 China 8.7 Japan 8.8 South Korea 8.9 Australia 8.10 India 8.11 Southeast Asia 8.11.1 Indonesia 8.11.2 Vietnam 8.11.3 Malaysia 8.11.4 Philippines 8.11.5 Singapore 9 Central and South America 9.1 Central and South America Market Size (2021-2032) 9.2 Central and South America Key Players’ Revenue in 2025 9.3 Central and South America Killed-type Poultry Vaccine Market Size by Application (2021-2032) 9.4 Central and South America Investment Opportunities and Key Challenges 9.5 Central and South America Killed-type Poultry Vaccine Market Size by Country 9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032) 9.5.2 Brazil 9.5.3 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Market Size (2021-2032) 10.2 Middle East and Africa Key Players’ Revenue in 2025 10.3 Middle East and Africa Killed-type Poultry Vaccine Market Size by Application (2021-2032) 10.4 Middle East and Africa Investment Opportunities and Key Challenges 10.5 Middle East and Africa Killed-type Poultry Vaccine Market Size by Country 10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032) 10.5.2 GCC Countries 10.5.3 Israel 10.5.4 Egypt 10.5.5 South Africa 11 Corporate Profile 11.1 MSD Animal Health(Merck) 11.1.1 MSD Animal Health(Merck) Corporation Information 11.1.2 MSD Animal Health(Merck) Business Overview 11.1.3 MSD Animal Health(Merck) Killed-type Poultry Vaccine Product Features and Attributes 11.1.4 MSD Animal Health(Merck) Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.1.5 MSD Animal Health(Merck) Killed-type Poultry Vaccine Revenue by Product in 2025 11.1.6 MSD Animal Health(Merck) Killed-type Poultry Vaccine Revenue by Application in 2025 11.1.7 MSD Animal Health(Merck) Killed-type Poultry Vaccine Revenue by Geographic Area in 2025 11.1.8 MSD Animal Health(Merck) Killed-type Poultry Vaccine SWOT Analysis 11.1.9 MSD Animal Health(Merck) Recent Developments 11.2 Zoetis 11.2.1 Zoetis Corporation Information 11.2.2 Zoetis Business Overview 11.2.3 Zoetis Killed-type Poultry Vaccine Product Features and Attributes 11.2.4 Zoetis Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.2.5 Zoetis Killed-type Poultry Vaccine Revenue by Product in 2025 11.2.6 Zoetis Killed-type Poultry Vaccine Revenue by Application in 2025 11.2.7 Zoetis Killed-type Poultry Vaccine Revenue by Geographic Area in 2025 11.2.8 Zoetis Killed-type Poultry Vaccine SWOT Analysis 11.2.9 Zoetis Recent Developments 11.3 Boehringer Ingelheim 11.3.1 Boehringer Ingelheim Corporation Information 11.3.2 Boehringer Ingelheim Business Overview 11.3.3 Boehringer Ingelheim Killed-type Poultry Vaccine Product Features and Attributes 11.3.4 Boehringer Ingelheim Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.3.5 Boehringer Ingelheim Killed-type Poultry Vaccine Revenue by Product in 2025 11.3.6 Boehringer Ingelheim Killed-type Poultry Vaccine Revenue by Application in 2025 11.3.7 Boehringer Ingelheim Killed-type Poultry Vaccine Revenue by Geographic Area in 2025 11.3.8 Boehringer Ingelheim Killed-type Poultry Vaccine SWOT Analysis 11.3.9 Boehringer Ingelheim Recent Developments 11.4 Ceva Santé Animale 11.4.1 Ceva Santé Animale Corporation Information 11.4.2 Ceva Santé Animale Business Overview 11.4.3 Ceva Santé Animale Killed-type Poultry Vaccine Product Features and Attributes 11.4.4 Ceva Santé Animale Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.4.5 Ceva Santé Animale Killed-type Poultry Vaccine Revenue by Product in 2025 11.4.6 Ceva Santé Animale Killed-type Poultry Vaccine Revenue by Application in 2025 11.4.7 Ceva Santé Animale Killed-type Poultry Vaccine Revenue by Geographic Area in 2025 11.4.8 Ceva Santé Animale Killed-type Poultry Vaccine SWOT Analysis 11.4.9 Ceva Santé Animale Recent Developments 11.5 Elanco Animal Health 11.5.1 Elanco Animal Health Corporation Information 11.5.2 Elanco Animal Health Business Overview 11.5.3 Elanco Animal Health Killed-type Poultry Vaccine Product Features and Attributes 11.5.4 Elanco Animal Health Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.5.5 Elanco Animal Health Killed-type Poultry Vaccine Revenue by Product in 2025 11.5.6 Elanco Animal Health Killed-type Poultry Vaccine Revenue by Application in 2025 11.5.7 Elanco Animal Health Killed-type Poultry Vaccine Revenue by Geographic Area in 2025 11.5.8 Elanco Animal Health Killed-type Poultry Vaccine SWOT Analysis 11.5.9 Elanco Animal Health Recent Developments 11.6 HIPRA 11.6.1 HIPRA Corporation Information 11.6.2 HIPRA Business Overview 11.6.3 HIPRA Killed-type Poultry Vaccine Product Features and Attributes 11.6.4 HIPRA Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.6.5 HIPRA Recent Developments 11.7 Vaxxinova 11.7.1 Vaxxinova Corporation Information 11.7.2 Vaxxinova Business Overview 11.7.3 Vaxxinova Killed-type Poultry Vaccine Product Features and Attributes 11.7.4 Vaxxinova Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.7.5 Vaxxinova Recent Developments 11.8 QYH Biotech 11.8.1 QYH Biotech Corporation Information 11.8.2 QYH Biotech Business Overview 11.8.3 QYH Biotech Killed-type Poultry Vaccine Product Features and Attributes 11.8.4 QYH Biotech Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.8.5 QYH Biotech Recent Developments 11.9 Pulike 11.9.1 Pulike Corporation Information 11.9.2 Pulike Business Overview 11.9.3 Pulike Killed-type Poultry Vaccine Product Features and Attributes 11.9.4 Pulike Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.9.5 Pulike Recent Developments 11.10 Harbin Pharmaceutical Group 11.10.1 Harbin Pharmaceutical Group Corporation Information 11.10.2 Harbin Pharmaceutical Group Business Overview 11.10.3 Harbin Pharmaceutical Group Killed-type Poultry Vaccine Product Features and Attributes 11.10.4 Harbin Pharmaceutical Group Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.10.5 Company Ten Recent Developments 11.11 Nisseiken 11.11.1 Nisseiken Corporation Information 11.11.2 Nisseiken Business Overview 11.11.3 Nisseiken Killed-type Poultry Vaccine Product Features and Attributes 11.11.4 Nisseiken Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.11.5 Nisseiken Recent Developments 11.12 Hester Biosciences 11.12.1 Hester Biosciences Corporation Information 11.12.2 Hester Biosciences Business Overview 11.12.3 Hester Biosciences Killed-type Poultry Vaccine Product Features and Attributes 11.12.4 Hester Biosciences Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.12.5 Hester Biosciences Recent Developments 11.13 Globion India 11.13.1 Globion India Corporation Information 11.13.2 Globion India Business Overview 11.13.3 Globion India Killed-type Poultry Vaccine Product Features and Attributes 11.13.4 Globion India Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.13.5 Globion India Recent Developments 11.14 Venkys India 11.14.1 Venkys India Corporation Information 11.14.2 Venkys India Business Overview 11.14.3 Venkys India Killed-type Poultry Vaccine Product Features and Attributes 11.14.4 Venkys India Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.14.5 Venkys India Recent Developments 11.15 Bioveta 11.15.1 Bioveta Corporation Information 11.15.2 Bioveta Business Overview 11.15.3 Bioveta Killed-type Poultry Vaccine Product Features and Attributes 11.15.4 Bioveta Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.15.5 Bioveta Recent Developments 11.16 Jilin Zhengye 11.16.1 Jilin Zhengye Corporation Information 11.16.2 Jilin Zhengye Business Overview 11.16.3 Jilin Zhengye Killed-type Poultry Vaccine Product Features and Attributes 11.16.4 Jilin Zhengye Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.16.5 Jilin Zhengye Recent Developments 11.17 Yebio 11.17.1 Yebio Corporation Information 11.17.2 Yebio Business Overview 11.17.3 Yebio Killed-type Poultry Vaccine Product Features and Attributes 11.17.4 Yebio Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.17.5 Yebio Recent Developments 11.18 Sinder 11.18.1 Sinder Corporation Information 11.18.2 Sinder Business Overview 11.18.3 Sinder Killed-type Poultry Vaccine Product Features and Attributes 11.18.4 Sinder Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.18.5 Sinder Recent Developments 11.19 DHN 11.19.1 DHN Corporation Information 11.19.2 DHN Business Overview 11.19.3 DHN Killed-type Poultry Vaccine Product Features and Attributes 11.19.4 DHN Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.19.5 DHN Recent Developments 11.20 JinYu Biotechnology 11.20.1 JinYu Biotechnology Corporation Information 11.20.2 JinYu Biotechnology Business Overview 11.20.3 JinYu Biotechnology Killed-type Poultry Vaccine Product Features and Attributes 11.20.4 JinYu Biotechnology Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.20.5 JinYu Biotechnology Recent Developments 11.21 Guangzhou South China Biological Medicine 11.21.1 Guangzhou South China Biological Medicine Corporation Information 11.21.2 Guangzhou South China Biological Medicine Business Overview 11.21.3 Guangzhou South China Biological Medicine Killed-type Poultry Vaccine Product Features and Attributes 11.21.4 Guangzhou South China Biological Medicine Killed-type Poultry Vaccine Revenue and Gross Margin (2021-2026) 11.21.5 Guangzhou South China Biological Medicine Recent Developments 12 Killed-type Poultry Vaccine Value Chain and Ecosystem Analysis 12.1 Killed-type Poultry Vaccine Value Chain (Ecosystem Structure) 12.2 Upstream Analysis 12.2.1 Key Technologies, Platforms and Infrastructure 12.3 Midstream Analysis 12.4 Downstream Sales Model and Distribution Networks 12.4.1 Sales Channels 12.4.2 Distributors 13 Killed-type Poultry Vaccine Market Dynamics 13.1 Industry Trends and Evolution 13.2 Market Growth Drivers and Emerging Opportunities 13.3 Market Challenges, Risks, and Restraints 14 Key Findings in the Global Killed-type Poultry Vaccine Study 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.1.1 Research Programs/Design 15.1.1.2 Market Size Estimation 15.1.1.3 Market Breakdown and Data Triangulation 15.1.2 Data Source 15.1.2.1 Secondary Sources 15.1.2.2 Primary Sources 15.2 Author Details List of Tables/GraphsList of TablesTable 1. Global Killed-type Poultry Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Table 2. Global Killed-type Poultry Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million) Table 3. Global Killed-type Poultry Vaccine Market Size Growth Rate by Function, 2021 vs 2025 vs 2032 (US$ Million) Table 4. Global Killed-type Poultry Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Table 5. Global Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 6. Global Killed-type Poultry Vaccine Revenue by Region (US$ Million), 2021-2026 Table 7. Global Killed-type Poultry Vaccine Revenue by Region (US$ Million), 2027-2032 Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 9. Global Killed-type Poultry Vaccine Revenue by Players (US$ Million), 2021-2026 Table 10. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Players (2021-2026) Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue) Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Killed-type Poultry Vaccine Revenue, 2025 Table 13. Global Killed-type Poultry Vaccine Average Gross Margin (%) by Player (2021 vs 2025) Table 14. Global Killed-type Poultry Vaccine Companies Headquarters Table 15. Global Killed-type Poultry Vaccine Market Concentration Ratio (CR5) Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment Table 18. Global Killed-type Poultry Vaccine Revenue by Type (US$ Million), 2021-2026 Table 19. Global Killed-type Poultry Vaccine Revenue by Type (US$ Million), 2027-2032 Table 20. Global Killed-type Poultry Vaccine Revenue by Antigen Combination (US$ Million), 2021-2026 Table 21. Global Killed-type Poultry Vaccine Revenue by Antigen Combination (US$ Million), 2027-2032 Table 22. Global Killed-type Poultry Vaccine Revenue by Function (US$ Million), 2021-2026 Table 23. Global Killed-type Poultry Vaccine Revenue by Function (US$ Million), 2027-2032 Table 24. Key Product Attributes and Differentiation Table 25. Global Killed-type Poultry Vaccine Revenue by Application (US$ Million), 2021-2026 Table 26. Global Killed-type Poultry Vaccine Revenue by Application (US$ Million), 2027-2032 Table 27. Killed-type Poultry Vaccine High-Growth Sectors Demand CAGR (2026-2032) Table 28. Top Customers by Region Table 29. Top Customers by Application Table 30. North America Killed-type Poultry Vaccine Growth Accelerators and Market Barriers Table 31. North America Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 32. Europe Killed-type Poultry Vaccine Growth Accelerators and Market Barriers Table 33. Europe Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million) Table 34. Asia-Pacific Killed-type Poultry Vaccine Growth Accelerators and Market Barriers Table 35. Asia-Pacific Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 36. Central and South America Killed-type Poultry Vaccine Investment Opportunities and Key Challenges Table 37. Central and South America Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 38. Middle East and Africa Killed-type Poultry Vaccine Investment Opportunities and Key Challenges Table 39. Middle East and Africa Killed-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 40. MSD Animal Health(Merck) Corporation Information Table 41. MSD Animal Health(Merck) Description and Major Businesses Table 42. MSD Animal Health(Merck) Product Features and Attributes Table 43. MSD Animal Health(Merck) Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. MSD Animal Health(Merck) Revenue Proportion by Product in 2025 Table 45. MSD Animal Health(Merck) Revenue Proportion by Application in 2025 Table 46. MSD Animal Health(Merck) Revenue Proportion by Geographic Area in 2025 Table 47. MSD Animal Health(Merck) Killed-type Poultry Vaccine SWOT Analysis Table 48. MSD Animal Health(Merck) Recent Developments Table 49. Zoetis Corporation Information Table 50. Zoetis Description and Major Businesses Table 51. Zoetis Product Features and Attributes Table 52. Zoetis Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Zoetis Revenue Proportion by Product in 2025 Table 54. Zoetis Revenue Proportion by Application in 2025 Table 55. Zoetis Revenue Proportion by Geographic Area in 2025 Table 56. Zoetis Killed-type Poultry Vaccine SWOT Analysis Table 57. Zoetis Recent Developments Table 58. Boehringer Ingelheim Corporation Information Table 59. Boehringer Ingelheim Description and Major Businesses Table 60. Boehringer Ingelheim Product Features and Attributes Table 61. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Boehringer Ingelheim Revenue Proportion by Product in 2025 Table 63. Boehringer Ingelheim Revenue Proportion by Application in 2025 Table 64. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025 Table 65. Boehringer Ingelheim Killed-type Poultry Vaccine SWOT Analysis Table 66. Boehringer Ingelheim Recent Developments Table 67. Ceva Santé Animale Corporation Information Table 68. Ceva Santé Animale Description and Major Businesses Table 69. Ceva Santé Animale Product Features and Attributes Table 70. Ceva Santé Animale Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Ceva Santé Animale Revenue Proportion by Product in 2025 Table 72. Ceva Santé Animale Revenue Proportion by Application in 2025 Table 73. Ceva Santé Animale Revenue Proportion by Geographic Area in 2025 Table 74. Ceva Santé Animale Killed-type Poultry Vaccine SWOT Analysis Table 75. Ceva Santé Animale Recent Developments Table 76. Elanco Animal Health Corporation Information Table 77. Elanco Animal Health Description and Major Businesses Table 78. Elanco Animal Health Product Features and Attributes Table 79. Elanco Animal Health Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Elanco Animal Health Revenue Proportion by Product in 2025 Table 81. Elanco Animal Health Revenue Proportion by Application in 2025 Table 82. Elanco Animal Health Revenue Proportion by Geographic Area in 2025 Table 83. Elanco Animal Health Killed-type Poultry Vaccine SWOT Analysis Table 84. Elanco Animal Health Recent Developments Table 85. HIPRA Corporation Information Table 86. HIPRA Description and Major Businesses Table 87. HIPRA Product Features and Attributes Table 88. HIPRA Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. HIPRA Recent Developments Table 90. Vaxxinova Corporation Information Table 91. Vaxxinova Description and Major Businesses Table 92. Vaxxinova Product Features and Attributes Table 93. Vaxxinova Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Vaxxinova Recent Developments Table 95. QYH Biotech Corporation Information Table 96. QYH Biotech Description and Major Businesses Table 97. QYH Biotech Product Features and Attributes Table 98. QYH Biotech Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. QYH Biotech Recent Developments Table 100. Pulike Corporation Information Table 101. Pulike Description and Major Businesses Table 102. Pulike Product Features and Attributes Table 103. Pulike Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Pulike Recent Developments Table 105. Harbin Pharmaceutical Group Corporation Information Table 106. Harbin Pharmaceutical Group Description and Major Businesses Table 107. Harbin Pharmaceutical Group Product Features and Attributes Table 108. Harbin Pharmaceutical Group Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Harbin Pharmaceutical Group Recent Developments Table 110. Nisseiken Corporation Information Table 111. Nisseiken Description and Major Businesses Table 112. Nisseiken Product Features and Attributes Table 113. Nisseiken Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Nisseiken Recent Developments Table 115. Hester Biosciences Corporation Information Table 116. Hester Biosciences Description and Major Businesses Table 117. Hester Biosciences Product Features and Attributes Table 118. Hester Biosciences Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Hester Biosciences Recent Developments Table 120. Globion India Corporation Information Table 121. Globion India Description and Major Businesses Table 122. Globion India Product Features and Attributes Table 123. Globion India Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Globion India Recent Developments Table 125. Venkys India Corporation Information Table 126. Venkys India Description and Major Businesses Table 127. Venkys India Product Features and Attributes Table 128. Venkys India Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Venkys India Recent Developments Table 130. Bioveta Corporation Information Table 131. Bioveta Description and Major Businesses Table 132. Bioveta Product Features and Attributes Table 133. Bioveta Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Bioveta Recent Developments Table 135. Jilin Zhengye Corporation Information Table 136. Jilin Zhengye Description and Major Businesses Table 137. Jilin Zhengye Product Features and Attributes Table 138. Jilin Zhengye Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Jilin Zhengye Recent Developments Table 140. Yebio Corporation Information Table 141. Yebio Description and Major Businesses Table 142. Yebio Product Features and Attributes Table 143. Yebio Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Yebio Recent Developments Table 145. Sinder Corporation Information Table 146. Sinder Description and Major Businesses Table 147. Sinder Product Features and Attributes Table 148. Sinder Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Sinder Recent Developments Table 150. DHN Corporation Information Table 151. DHN Description and Major Businesses Table 152. DHN Product Features and Attributes Table 153. DHN Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. DHN Recent Developments Table 155. JinYu Biotechnology Corporation Information Table 156. JinYu Biotechnology Description and Major Businesses Table 157. JinYu Biotechnology Product Features and Attributes Table 158. JinYu Biotechnology Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. JinYu Biotechnology Recent Developments Table 160. Guangzhou South China Biological Medicine Corporation Information Table 161. Guangzhou South China Biological Medicine Description and Major Businesses Table 162. Guangzhou South China Biological Medicine Product Features and Attributes Table 163. Guangzhou South China Biological Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 164. Guangzhou South China Biological Medicine Recent Developments Table 165. Technologies, Platforms and Infrastructure Table 166. Distributors List Table 167. Market Trends and Market Evolution Table 168. Market Drivers and Opportunities Table 169. Market Challenges, Risks, and Restraints Table 170. Research Programs/Design for This Report Table 171. Key Data Information from Secondary Sources Table 172. Key Data Information from Primary Sources List of Figures Figure 1. Global Killed-type Poultry Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Figure 2. Newcastle Disease Vaccines Product Picture Figure 3. Infectious Bronchitis Vaccines Product Picture Figure 4. Others Product Picture Figure 5. Global Killed-type Poultry Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million) Figure 6. Monovalent Vaccines Product Picture Figure 7. Multivalent / Combination Vaccines Product Picture Figure 8. Global Killed-type Poultry Vaccine Market Size Growth Rate by Function, 2021 vs 2025 vs 2032 (US$ Million) Figure 9. Preventive Vaccines Product Picture Figure 10. Prime Vaccines Product Picture Figure 11. Booster Vaccines Product Picture Figure 12. Global Killed-type Poultry Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Figure 13. Broiler Farming Figure 14. Layer Farming Figure 15. Breeder Farming Figure 16. Others Figure 17. Killed-type Poultry Vaccine Report Years Considered Figure 18. Global Killed-type Poultry Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032 Figure 19. Global Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 20. Global Killed-type Poultry Vaccine Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Figure 21. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Region (2021-2032) Figure 22. Global Killed-type Poultry Vaccine Revenue-Based Market Share Ranking (2025) Figure 23. Tier Distribution by Revenue Contribution (2021 vs 2025) Figure 24. Newcastle Disease Vaccines Revenue-Based Market Share by Player in 2025 Figure 25. Infectious Bronchitis Vaccines Revenue-Based Market Share by Player in 2025 Figure 26. Others Revenue-Based Market Share by Player in 2025 Figure 27. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Type (2021-2032) Figure 28. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Antigen Combination (2021-2032) Figure 29. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Function (2021-2032) Figure 30. Global Killed-type Poultry Vaccine Revenue-Based Market Share by Application (2021-2032) Figure 31. North America Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 32. North America Top 5 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025 Figure 33. North America Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 34. US Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 35. Canada Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 36. Mexico Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 37. Europe Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 38. Europe Top 5 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025 Figure 39. Europe Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 40. Germany Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 41. France Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 42. U.K. Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 43. Italy Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 44. Russia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 45. Asia-Pacific Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 46. Asia-Pacific Top 8 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025 Figure 47. Asia-Pacific Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 48. Indonesia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 49. Japan Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 50. South Korea Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 51. Australia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 52. India Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 53. Indonesia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 54. Vietnam Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 55. Malaysia Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 56. Philippines Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 57. Singapore Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 58. Central and South America Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 59. Central and South America Top 5 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025 Figure 60. Central and South America Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 61. Brazil Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 62. Argentina Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 63. Middle East and Africa Killed-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 64. Middle East and Africa Top 5 Players Killed-type Poultry Vaccine Revenue (US$ Million) in 2025 Figure 65. Middle East and Africa Killed-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 66. GCC Countries Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 67. Israel Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 68. Egypt Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 69. South Africa Killed-type Poultry Vaccine Revenue (US$ Million), 2021-2032 Figure 70. Killed-type Poultry Vaccine Value Chain Mapping Figure 71. Channels of Distribution (Direct Vs Distribution) Figure 72. Bottom-up and Top-down Approaches for This Report Figure 73. Data Triangulation Figure 74. Key Executives Interviewed
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療/ヘルスケア)の最新刊レポート
QYResearch社の 医薬・ヘルスケア分野 での最新刊レポート本レポートと同じKEY WORD(poultry)の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|